MedTrace Logo

Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis

NCT01681940 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-03-29

No results posted yet for this study

Summary

The overall objective is to evaluate the long-term efficacy, safety and tolerability of repeated Lamazym i.v. treatment in patients 5-21 years of age with alpha-Mannosidosis

Conditions

  • Alpha-Mannosidosis

Interventions

DRUG

Lamazym

ERT, i.v. infusions weekly

Sponsors & Collaborators

Principal Investigators

  • Allan M Lund, MD · Copenhagen University Hospital, Center for Metabolic Diseases, Department for Clinical Genetics

  • Jens Fogh · Zymenex A/S

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-08-31
Completion
2013-09-30

Countries

  • Belgium
  • Denmark
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01681940 on ClinicalTrials.gov